Sanofi Optimistic On Dengue Vaccine In India Despite Waiver Blow
This article was originally published in PharmAsia News
Sanofi believes it can work out a deal with Indian regulators that will not delay access to its new dengue vaccine in the country after a health ministry panel refused its request to waive local Phase III trials.
You may also be interested in...
In the face of a growing outbreak in the country, Sanofi has urged India’s government to waive its insistence on local Phase III clinical trials for its vaccine to prevent dengue, warning that insistence on the development program could delay the Indian introduction of Dengvaxia by three years, amid rising medical need.
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.